Immunic reports CALLIPER extension data showing sustained disability outcomes for vidofludimus calcium in progressive MS through week 48
IMUX•Immunic reported Phase 2 CALLIPER open-label extension results for vidofludimus calcium in progressive multiple sclerosis, with disability outcomes favoring continuous treatment through week 48. The data will be presented Oct. 21-23 at MSToronto2026.
1. Extension findings
The CALLIPER extension follow-up favored continuous treatment on disability outcomes, with low discontinuation rates through week 48. Separate analyses linked reduced EBV-related immune activity to better cognitive performance, while preclinical work suggested Nurr1-dependent neuronal survival effects.
